The California-based company, fresh off receiving expanded Medicare coverage and a new Category I CPT code for its AI offerings, will have a significant presence at TCT 2024. 

Getting technologists, physicians and administrators to work together is a crucial part of any PET program. Research is also essential. Cardiovascular Business spoke to a specialist on the topic to learn more.

Baroreflex activation therapy with the Barostim device from CVRx has received new CPT codes from the American Medical Association. The codes go into effect in January 2026.

The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision. 

Shockwave Medical, now a part of Johnson & Johnson MedTech, continues to gain momentum among U.S. cardiologists. According to one MedAxiom executive, IVL "brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease."

ACR, the Society of Interventional Radiology and others recently submitted a letter to 5 of the 7 contractors, expressing concern about trigger-point injections. 

Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice. 

"We are failing to rescue women after high-risk surgery," one researcher said after reviewing years of Medicare data.